Selected article for: "abundant protein and adhesion cell migration"

Author: Ge, Yun; Huang, Man; Yao, Yong-ming
Title: The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases
  • Cord-id: zp2ci1ki
  • Document date: 2021_4_28
  • ID: zp2ci1ki
    Snippet: High mobility group box-1 protein (HMGB1), a member of the high mobility group protein superfamily, is an abundant and ubiquitously expressed nuclear protein. Intracellular HMGB1 is released by immune and necrotic cells and secreted HMGB1 activates a range of immune cells, contributing to the excessive release of inflammatory cytokines and promoting processes such as cell migration and adhesion. Moreover, HMGB1 is a typical damage-associated molecular pattern molecule that participates in variou
    Document: High mobility group box-1 protein (HMGB1), a member of the high mobility group protein superfamily, is an abundant and ubiquitously expressed nuclear protein. Intracellular HMGB1 is released by immune and necrotic cells and secreted HMGB1 activates a range of immune cells, contributing to the excessive release of inflammatory cytokines and promoting processes such as cell migration and adhesion. Moreover, HMGB1 is a typical damage-associated molecular pattern molecule that participates in various inflammatory and immune responses. In these ways, it plays a critical role in the pathophysiology of inflammatory diseases. Herein, we review the effects of HMGB1 on various immune cell types and describe the molecular mechanisms by which it contributes to the development of inflammatory disorders. Finally, we address the therapeutic potential of targeting HMGB1.

    Search related documents:
    Co phrase search for related documents
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and liver damage: 1, 2, 3, 4, 5, 6
    • acute phase and liver dysfunction: 1, 2, 3, 4
    • acute phase and liver failure: 1, 2, 3, 4, 5
    • acute phase and liver injury: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and local inflammation: 1, 2
    • acute phase and low concentration: 1, 2, 3
    • acute phase and lps exposure: 1
    • acute phase and lps stimulation: 1
    • acute phase and lung condition: 1
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute phase and lung edema: 1, 2, 3
    • acute phase and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
    • acute phase and lupus erythematosus: 1, 2
    • acute phase and lymph node: 1, 2, 3, 4, 5
    • acute phase and lymphoid tissue: 1, 2
    • acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10